[{"id":"198522b7-100a-4569-a5b1-c2c7d2835c3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06195306","created_at":"2024-01-08T16:17:49.869Z","updated_at":"2025-02-25T13:42:01.381Z","phase":"Phase 2","brief_title":"Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","source_id_and_acronym":"NCT06195306","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FOXA1 • AGR2 • LEP","pipe":"","alterations":" ","tags":["FOXA1 • AGR2 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-21"},{"id":"7122b640-e8c3-4f66-a9cf-75e23b76f6c1","acronym":"WinPro","url":"https://clinicaltrials.gov/study/NCT03906669","created_at":"2021-01-18T19:13:54.012Z","updated_at":"2024-07-02T16:35:28.353Z","phase":"Phase 2","brief_title":"A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.","source_id_and_acronym":"NCT03906669 - WinPro","lead_sponsor":"St Vincent's Hospital","biomarkers":" HER-2 • BCL2 • AR • CCND1 • FOXA1 • CASP3","pipe":" | ","alterations":" HER-2 negative • CCND1 expression","tags":["HER-2 • BCL2 • AR • CCND1 • FOXA1 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-11-22"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"fa58d62b-eb7a-4259-85da-03ca35c7b9bd","acronym":"CHORDOMES","url":"https://clinicaltrials.gov/study/NCT04486820","created_at":"2021-01-18T21:32:20.614Z","updated_at":"2024-07-02T16:36:42.757Z","phase":"","brief_title":"Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care","source_id_and_acronym":"NCT04486820 - CHORDOMES","lead_sponsor":"Centre Hospitalier Universitaire de Saint Etienne","biomarkers":" PD-L1 • CD8 • FOXA1 • CDX2 • INSM1","pipe":" | ","alterations":" PD-L1 expression • CDX-2 expression","tags":["PD-L1 • CD8 • FOXA1 • CDX2 • INSM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CDX-2 expression"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2020-07-27"}]